Investigators on Wednesday launched the primary detailed case report a couple of affected person who died after receiving lecanemab, offering a brand new glimpse into security considerations surrounding the intently watched experimental Alzheimer’s drug.
An unpublished model of the report was beforehand written about by Science in November, one in every of three deaths from the lecanemab trials revealed by Science and STAT. However the printed model, within the New England Journal of Drugs, will permit docs to guage the case as they take into account whether or not and learn how to use a remedy that may very well be accepted by the FDA as quickly as this week.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED